None
Skip to mainSree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Thiruvananthapuram, has developed a path-breaking drug delivery system for cancer treatment with a single-molecule chemical derived from a plant commonly seen in the country and across the world.
The institute has completed a successful trial in animals and will soon proceed with clinical trials in humans after fixing a safe dosage for this cytotoxic drug.
Coded SCTAC2010 – intellectual property rights prevent the institute from disclosing the name of the plant or the chemical derived for now – the drug is a conjugation of a particular chemical with anti-cancer properties and albumin, a protein abundant in human blood, for intravenous administration.
SCTIMST director Asha Kishore said there will be a few more phases of clinical trials and involvement of industry partners before the drug can get final approval from authorities like the Drugs Controller General of India.
“This formulation has been proven to destroy cancer cells. We are transferring this technology to our industry partner with great hopes,” she said.
The project has funding from the Indian Council of Medical Research for this project.
‘More studies needed to get the regulatory nod for trial in human beings’ Such molecules extracted from plants are insoluble in water but soluble only in organic solvents like chloroform. Many universities and research institutes often prove in labs the anticancer properties of chemicals derived from plants and publish papers. But such attempts do not benefit patients, as these molecules are insoluble in water and cannot reach the cancer tissues,” said Dr Lissy Krishnan, the senior scientist at SCTIMST and the lead investigator.
The task was to find a formulation where this pure molecule, which is known for its biological properties and available in the international market, could be made water soluble. “And, we successfully conjugated the chemical drug to albumin, a natural drug-carrier in human blood with therapeutic applications,” Dr Krishnan said.
Dr Krishnan and her team started research in 2010. “As it’s a cytotoxic drug, we need to get the right kind of concentration for multiple dosage therapies. Though we have found it safe in animals, a few more studies have to be done to get regulatory approvals for trial in human beings. More data needs to be generated for the approvals, and we will go for the Phase I clinical study in normal volunteers and then select volunteers,” said Dr Krishnan.
“We have to bring a balance between the toxic molecule and the non-toxic albumin. It will take one to two years for this time-consuming testing,” she added.
🕑 18 Apr, 2024 11:51 AM
Timeline extended for CGHS Beneficiary ID - ABHA ID linking
🕑 18 Apr, 2024 10:22 AM
APAR timelines for Central Civil Services extended to 30th April
🕑 10 Apr, 2024 08:25 AM
DoPT Guidelines on Departmental Promotion Committees
🕑 02 Apr, 2024 09:21 AM
CGHS ID - ABHA linking mandatory and needs to be done in 30 days
🕑 31 Mar, 2024 08:10 PM
DA from 01.01.2024 to Armed Forces Officers & Personnel Below Officer Rank
🕑 31 Mar, 2024 08:10 PM
DA from 01.01.2024 to Armed Forces Officers & Personnel Below Officer Rank
🕑 31 Mar, 2024 08:07 PM
DoP: Guidelines for transfer to regulate transfers in March 2024
🕑 31 Mar, 2024 08:02 PM
CDA: Clarification of Date of next increment under Rule 10 of CCS
🕑 10 Apr, 2024 08:35 AM
Kendriya Vidyalaya Sangathan Admission Guidelines 2024-2025
🕑 05 Apr, 2024 01:23 PM
Kendriya Vidyalaya Balvatika Admission Schedule - 2024-25
🕑 02 Apr, 2024 09:25 AM
Kendriya Vidyalaya Admissions Open for 2024-25: Key Dates & Appln Process
🕑 01 Apr, 2024 09:23 AM
Kendriya Vidyalaya (KV) schools where Balvatika is functioning
🕑 14 Mar, 2024 02:07 PM
Govt bans 18 vulgar 18 OTT. See the list here
🕑 08 Mar, 2024 01:49 PM
Pension Scheme Gains Traction Across States, Despite Central Hurdles
🕑 20 Feb, 2024 11:17 PM
CGHS rate for general surgery applicable from February 1, 2024
🕑 08 Feb, 2024 10:19 AM
No loan interst change as RBI maintains repo rate at 6.50% for the 6th time